Drug Profile


Alternative Names: VAS-203

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator vasopharm BIOTECH
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Brain injuries

Most Recent Events

  • 01 Nov 2016 vasopharma BIOTECH completes a phase I pharmacodynamics trial in Healthy volunteers Germany (IV) (NCT02992236)
  • 07 Oct 2016 Chemical structure information added
  • 22 Sep 2016 Phase-III clinical trials in Brain injuries in France (IV) (NCT02794168)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top